Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Gross Margin (2016 - 2026)

Heron Therapeutics filings provide 11 years of Gross Margin readings, the most recent being 69.35% for Q1 2026.

  • On a quarterly basis, Gross Margin fell 891.0% to 69.35% in Q1 2026 year-over-year; TTM through Mar 2026 was 71.12%, a 285.0% decrease, with the full-year FY2025 number at 73.31%, up 9.0% from a year prior.
  • Gross Margin hit 69.35% in Q1 2026 for Heron Therapeutics, down from 72.61% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 78.26% in Q1 2025 to a low of 36.53% in Q2 2023.
  • Median Gross Margin over the past 5 years was 69.35% (2026), compared with a mean of 61.38%.
  • Biggest five-year swings in Gross Margin: surged 21018bps in 2022 and later crashed -891bps in 2026.
  • Heron Therapeutics' Gross Margin stood at 57.95% in 2022, then increased by 23bps to 71.12% in 2023, then rose by 5bps to 74.92% in 2024, then fell by -3bps to 72.61% in 2025, then decreased by -4bps to 69.35% in 2026.
  • The last three reported values for Gross Margin were 69.35% (Q1 2026), 72.61% (Q4 2025), and 68.82% (Q3 2025) per Business Quant data.